학술논문

발행년
-
(예 : 2010-2015)
'학술논문' 에서 검색결과 14건 | 목록 1~10
Academic Journal
Hamilton E; Sarah Cannon Research Institute, Nashville, USA.; Oliveira M; Medical Oncology Department, Vall d'Hebron University Hospital and Breast Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Turner N; Breast Cancer Now, Toby Robins Research Centre, Institute of Cancer Research, London, UK.; García-Corbacho J; ICMHO Clinical Trials Unit, Hospital Clinic, Barcelona.; Hernando C; Department of Medical Oncology, Hospital Clinico Universitario de Valencia, Biomedical Research Institute (INCLIVA), Valencia.; Ciruelos EM; Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain.; Kabos P; Division of Medical Oncology, University of Colorado, Denver, USA.; Ruiz-Borrego M; Department of Medical Oncology, H U Virgen del Rocio, Seville, Spain.; Armstrong A; The Christie NHS Foundation Trust and the University of Manchester, Manchester, UK.; Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute/Sarasota Memorial Hospital, Sarasota.; Vaklavas C; Huntsman Cancer Institute, University of Utah, Salt Lake City, USA.; Twelves C; Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK.; Boni V; START Madrid, CIOCC, Madrid, Spain.; Incorvati J; Fox Chase Cancer Center, East Norriton-Hospital Outpatient Center, Philadelphia, USA.; Brier T; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge.; Gibbons L; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge.; Klinowska T; Late Development, Oncology R&D, AstraZeneca, Cambridge.; Lindemann JPO; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge.; Morrow CJ; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge.; Sykes A; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge.; Baird RD; Cancer Research UK, Cambridge Centre, Cambridge, UK. Electronic address: rdb39@cam.ac.uk.
Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Academic Journal
Lawson M; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Cureton N; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Ros S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Cheraghchi-Bashi A; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Urosevic J; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; D'Arcy S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Delpuech O; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; DuPont M; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts.; Fisher DI; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Gangl ET; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts.; Lewis H; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Trueman D; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Wali N; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Williamson SC; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Moss J; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Montaudon E; Institut Curie, Paris, France.; Derrien H; Institut Curie, Paris, France.; Marangoni E; Institut Curie, Paris, France.; Miragaia RJ; Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Gagrica S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Morentin-Gutierrez P; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Moss TA; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Maglennon G; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Sutton D; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Polanski R; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Rosen A; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts.; Cairns J; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Zhang P; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Sánchez-Guixé M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Critchlow SE; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Scott JS; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Lindemann JPO; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Barry ST; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Klinowska T; Late Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Morrow CJ; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.; Carnevalli LS; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE
Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: PubMed not MEDLINE; MEDLINE
Academic Journal
Smyth LM; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Loxo Oncology Inc., Stamford, CT, USA.; Batist G; Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada.; Meric-Bernstam F; MD Anderson Cancer Center, Houston, TX, USA.; Kabos P; University of Colorado Cancer Center, Aurora, CO, USA.; Spanggaard I; Rigshospitalet, Copenhagen, Denmark.; Lluch A; Hospital Clínico Universitario de Valencia, University of Valencia, INCLIVA Biomedical Research Institute, Valencia, Spain.; Biomedical Research Centre Network in Cancer (CIBERONC), Madrid, Spain.; Jhaveri K; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Varga A; Institute Gustave Roussy, Villejuif, France.; Wong A; National University Hospital, Singapore, Singapore.; Schram AM; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Ambrose H; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Carr TH; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; de Bruin EC; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Salinas-Souza C; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Foxley A; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Hauser J; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Lindemann JPO; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Maudsley R; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; McEwen R; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Moschetta M; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Nikolaou M; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Schiavon G; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Razavi P; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Banerji U; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.; Baselga J; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; AstraZeneca, Gaithersburg, MD, USA.; Hyman DM; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Loxo Oncology Inc., Stamford, CT, USA.; Chandarlapaty S; Memorial Sloan Kettering Cancer Center, New York, NY, USA. chandars@mskcc.org.
Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE
Academic Journal
Yap TA; Royal Marsden Hospital, London, United Kingdom. tyap@mdanderson.org.; The Institute of Cancer Research, London, United Kingdom.; Kristeleit R; University College London, London, United Kingdom.; Michalarea V; Royal Marsden Hospital, London, United Kingdom.; Pettitt SJ; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom.; Lim JSJ; Royal Marsden Hospital, London, United Kingdom.; Carreira S; The Institute of Cancer Research, London, United Kingdom.; Roda D; Royal Marsden Hospital, London, United Kingdom.; The Institute of Cancer Research, London, United Kingdom.; Miller R; University College London, London, United Kingdom.; Riisnaes R; The Institute of Cancer Research, London, United Kingdom.; Miranda S; The Institute of Cancer Research, London, United Kingdom.; Figueiredo I; The Institute of Cancer Research, London, United Kingdom.; Rodrigues DN; The Institute of Cancer Research, London, United Kingdom.; Ward S; Royal Marsden Hospital, London, United Kingdom.; The Institute of Cancer Research, London, United Kingdom.; Matthews R; Royal Marsden Hospital, London, United Kingdom.; The Institute of Cancer Research, London, United Kingdom.; Parmar M; Royal Marsden Hospital, London, United Kingdom.; The Institute of Cancer Research, London, United Kingdom.; Turner A; Royal Marsden Hospital, London, United Kingdom.; The Institute of Cancer Research, London, United Kingdom.; Tunariu N; Royal Marsden Hospital, London, United Kingdom.; Chopra N; Royal Marsden Hospital, London, United Kingdom.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.; Gevensleben H; The Institute of Cancer Research, London, United Kingdom.; Turner NC; Royal Marsden Hospital, London, United Kingdom.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.; Ruddle R; The Institute of Cancer Research, London, United Kingdom.; Raynaud FI; The Institute of Cancer Research, London, United Kingdom.; Decordova S; The Institute of Cancer Research, London, United Kingdom.; Swales KE; The Institute of Cancer Research, London, United Kingdom.; Finneran L; The Institute of Cancer Research, London, United Kingdom.; Hall E; The Institute of Cancer Research, London, United Kingdom.; Rugman P; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Lindemann JPO; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Foxley A; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Lord CJ; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom.; Banerji U; Royal Marsden Hospital, London, United Kingdom.; The Institute of Cancer Research, London, United Kingdom.; Plummer R; Clinical and Translational Research Institute, Newcastle University, Newcastle, United Kingdom.; Basu B; Department of Oncology, University of Cambridge, Cambridge, United Kingdom.; Lopez JS; Royal Marsden Hospital, London, United Kingdom.; The Institute of Cancer Research, London, United Kingdom.; Drew Y; Clinical and Translational Research Institute, Newcastle University, Newcastle, United Kingdom.; de Bono JS; Royal Marsden Hospital, London, United Kingdom.; The Institute of Cancer Research, London, United Kingdom.
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Academic Journal
Robertson JFR; University of Nottingham, Nottingham, United Kingdom. john.robertson@nottingham.ac.uk.; Evans A; Poole Hospital, Poole, United Kingdom.; Henschen S; Helios Clinics Schwerin, Schwerin, Germany.; Kirwan CC; University of Manchester, Manchester, United Kingdom.; Jahan A; King's Mill Hospital, Mansfield, United Kingdom.; Kenny LM; Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom.; Dixon JM; Western General Hospital, Edinburgh, United Kingdom.; Schmid P; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Kothari A; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.; Mohamed O; Johannes Wesling General Hospital, Minden, Germany.; Fasching PA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Nuremberg, Germany.; Cheung KL; University of Nottingham, Nottingham, United Kingdom.; Wuerstlein R; Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center, University of Munich (LMU), Munich, Germany.; Carroll D; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Klinowska T; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Lindemann JPO; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; MacDonald A; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Mather R; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Maudsley R; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Moschetta M; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Nikolaou M; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Roudier MP; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Sarvotham T; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Schiavon G; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Zhou D; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Zhou L; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Harbeck N; Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center, University of Munich (LMU), Munich, Germany.
Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Academic Journal
Smyth LM; Memorial Sloan Kettering Cancer Center, New York, New York. lilsmyth@svhg.ie.; Tamura K; National Cancer Center Hospital, Tokyo, Japan.; Oliveira M; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Ciruelos EM; Hospital Universitario 12 de Octubre, Madrid, Spain.; Mayer IA; Vanderbilt Breast Center, Nashville, Tennessee.; Sablin MP; Institut Curie, Paris, France.; Biganzoli L; Breast Centre, Oncology Department, Hospital of Prato, Prato, Italy.; Ambrose HJ; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Ashton J; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Barnicle A; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Cashell DD; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Corcoran C; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; de Bruin EC; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Foxley A; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Hauser J; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Lindemann JPO; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Maudsley R; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; McEwen R; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Moschetta M; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Pass M; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Rowlands V; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Schiavon G; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.; Banerji U; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.; Scaltriti M; Memorial Sloan Kettering Cancer Center, New York, New York.; Taylor BS; Memorial Sloan Kettering Cancer Center, New York, New York.; Chandarlapaty S; Memorial Sloan Kettering Cancer Center, New York, New York.; Baselga J; Memorial Sloan Kettering Cancer Center, New York, New York.; Hyman DM; Memorial Sloan Kettering Cancer Center, New York, New York.
Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Academic Journal
Robertson JFR; University of Nottingham, Nottingham, UK. john.robertson@nottingham.ac.uk.; Coleman RE; University of Sheffield, Sheffield, UK.; Cheung KL; University of Nottingham, Royal Derby Hospital Centre, Derby, UK.; Evans A; Poole Hospital NHS Foundation Trust, Poole, UK.; Holcombe C; Royal Liverpool University Hospital, Liverpool, UK.; Skene A; Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK.; Rea D; University of Birmingham, Birmingham, UK.; Ahmed S; Leicester Royal Infirmary, Leicester, UK.; Jahan A; King's Mill Hospital, Nottingham, UK.; Horgan K; Leeds General Infirmary, Leeds, UK.; Rauchhaus P; University of Dundee, Dundee, UK.; Littleford R; University of Dundee, Dundee, UK.; Cheung SYA; IMED Biotech Unit, AstraZeneca, Cambridge, UK.; Cullberg M; IMED Biotech Unit, AstraZeneca, Cambridge, UK.; de Bruin EC; IMED Biotech Unit, AstraZeneca, Cambridge, UK.; Koulai L; IMED Biotech Unit, AstraZeneca, Cambridge, UK.; Lindemann JPO; IMED Biotech Unit, AstraZeneca, Cambridge, UK.; Pass M; IMED Biotech Unit, AstraZeneca, Cambridge, UK.; Rugman P; IMED Biotech Unit, AstraZeneca, Cambridge, UK.; Schiavon G; IMED Biotech Unit, AstraZeneca, Cambridge, UK.; Deb R; Department of Histopathology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.; Finlay P; Cardiff University, Cardiff, UK.; Foxley A; IMED Biotech Unit, AstraZeneca, Cambridge, UK.; Gee JMW; Cardiff University, Cardiff, UK.
Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Academic Journal
Turner NC; Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK. Electronic address: Nick.Turner@icr.ac.uk.; Alarcón E; Clinical Oncology Department, British American Hospital, Lima, Peru.; Armstrong AC; Department of Medical Oncology, Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.; Philco M; Peruvian Institute of Oncology Radiotherapy, Lima, Peru.; López Chuken YA; University Hospital, Monterrey, Mexico.; Sablin MP; Department of Drug Development and Innovation (D3i), Curie Institute, Paris, France.; Tamura K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Gómez Villanueva A; Clinical Oncology Unit, Private Hemato-Oncology Center, Toluca, Mexico.; Pérez-Fidalgo JA; Medical Oncology Unit, INCLIVA Biomedical Research Institute, University Clinical Hospital of Valencia, Valencia; CIBERONC, Health Institute Carlos III, Madrid, Spain.; Cheung SYA; IMED Biotech Unit, AstraZeneca, Cambridge.; Corcoran C; Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge.; Cullberg M; IMED Biotech Unit, AstraZeneca, Cambridge.; Davies BR; IMED Biotech Unit, AstraZeneca, Cambridge.; de Bruin EC; IMED Biotech Unit, AstraZeneca, Cambridge.; Foxley A; IMED Biotech Unit, AstraZeneca, Cambridge.; Lindemann JPO; IMED Biotech Unit, AstraZeneca, Cambridge.; Maudsley R; IMED Biotech Unit, AstraZeneca, Cambridge.; Moschetta M; IMED Biotech Unit, AstraZeneca, Cambridge.; Outhwaite E; Anchora Consultancy Ltd, Devon, UK.; Pass M; IMED Biotech Unit, AstraZeneca, Cambridge.; Rugman P; IMED Biotech Unit, AstraZeneca, Cambridge.; Schiavon G; IMED Biotech Unit, AstraZeneca, Cambridge.; Oliveira M; Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Lindemann, JPO
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어